Home    Back

Mt-1303 [0.4]    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica1

13. Multiple sclerosis/Neuromyelitis optica    [ 3,050 clinical trials,   2,147 drugs,   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways]
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 3,050 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2012-002639-27-IT
(EUCTR)		21/05/201311/04/2013A study to assess long-term safety and effectiveness of MT-1303 insubjects who completed the MT-1303-E04 study.A phase II, multicentre study to evaluate the long-term safety and efficacyof MT-1303 in subjects with relapsing-remitting multiple sclerosis whohave completed the MT-1303-E04 study Relapsing-remitting multiple sclerosis (RRMS);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: MT-1303 [0.1]
Product Code: MT-1303
Product Name: MT-1303 [0.2]
Product Code: MT-1303
Product Name: MT-1303 [0.4]
Product Code: MT-1303		MITSUBISHI TANABE PHARMA CORPORATIONNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		400Phase 2Serbia;Finland;Spain;Ukraine;Lithuania;Russian Federation;United Kingdom;Switzerland;Italy;Czech Republic;Hungary;Canada;Belgium;Poland;Croatia;Bulgaria;Germany;Latvia;Sweden;Bosnia and Herzegovina